Contact Lens Comfort Relative to Meibomian Gland Status
|ClinicalTrials.gov Identifier: NCT01819194|
Recruitment Status : Completed
First Posted : March 27, 2013
Results First Posted : December 9, 2014
Last Update Posted : June 17, 2016
|Condition or disease||Intervention/treatment||Phase|
|Meibomian Gland Dysfunction||Device: senofilcon A||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||64 participants|
|Intervention Model:||Single Group Assignment|
|Primary Purpose:||Supportive Care|
|Study Start Date :||March 2013|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||August 2013|
Experimental: senofilcon A
Acuvvue Oasys with Hydaclear Plus with 38% water.
|Device: senofilcon A|
- Comfort as Measured by the Contact Lens Users Experience Questionnaire (CLUE) [ Time Frame: Post 3 days of wear ]CLUE is survey that is used to assess subjective comfort of the test article. The higher the score the better on a range of 0 to 120.
- Meibbomian Gland Dysfunction (MGD)as Measured by MGD Scale [ Time Frame: Post 3 days of wear ]Meibomian Gland Dysfunction (MGD) as measured using the MGD 0 - 11 scale translated into grades 0 to 3 where 0 refers to absence of markers.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01819194
|United States, California|
|Fullerton, California, United States, 92831|